Alumis Inc
Research Alumis Inc (ALMS) on Bullrun: market cap USD 920.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALMS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 920.10M
- Financial periodQ2 2026
- RevenueUSD 1.66M
- Net income-USD 142.22M
- Free cash flow-USD 81.74M
Valuation Snapshot
latest market cap is USD 920.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 24.05M | -USD 243.33M | -USD 370.18M | n/a | -2.86 | USD 89.67M | USD 36.91M | USD 301.30M |
| FY2024 | USD 0 | -USD 294.23M | -USD 256.81M | n/a | -10.38 | USD 169.53M | USD 30.72M | USD 260.10M |
| FY2023 | USD 0 | -USD 154.99M | -USD 134.47M | n/a | -72.08 | USD 46.00M | USD 32.58M | -USD 339.26M |
| FY2022 | USD 0 | -USD 111.93M | -USD 110.13M | n/a | -2.91 | USD 25.61M | USD 1.78M | -USD 195.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 920.10M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.02B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 427.64M | n/a | n/a | n/a |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alumis Inc's market cap?
Alumis Inc's market capitalization is USD 920.10M.
What does Alumis Inc do?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.